Angiotensin–converting enzyme inhibitors (ACEi), such as captopril and liopelil, and mineralocorticoid receptor antagonists (MRA), like finerenone, are well-established in the treatment of DN and are included in current guidelines due to their efficacy in managing hypertension and cardiovascular diseases. Here, NR3C2 is linked to hypertensive disorder.